Skip to main content
OpenTrials
Completed

NCT Number: NCT05938205

Multicomponent Analysis of phYsical Frailty BiomarkErs: Focus on Mitochondrial Health - MAYBE

The study will be conducted in a group of obese sarcopenic patients (Sarco-Ob) aged > 60 years on moderately hypocaloric diet therapy aimed at comparing the effect of a strength exercise protocol, combined or not with dietary supplementation with amino acids, on physical performance, muscle strength, body composition, muscle oxidative metabolism, and biomarkers of sarcopenia. The supplementation study will be conducted in a double-blind manner.

Completed

Looking for future studies?

Notify Me

Key information

Age range

60 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

AOUI Verona

Verona, 37126, Italy

About this study

In this double-blind randomised control trial, older men, and women resident in Verona (Italy) will be selected from the Geriatrics Nutritional Clinic of the Borgo Trento Hospital or were contacted by telephone. A specific medical screening was initially programmed to verify the criteria of recruitment.

Anthropometric and body composition In the morning, in a fasted state, body mass will be taken with an electronic scale (Tanita electronic scale BWB-800 MA) and stature will be measured with a Harpenden stadiometer (Holtain Ltd., Crymych, Pembs. UK); BMI will be calculated as weight (kg)/height (m)2. Thereafter, total and regional body composition will be evaluated by means of dual-energy X-ray absorptiometry (DXA) using a total body scanner (QDR Horizon W, Hologic, MA, USA; fan-bean technology, software for Windows XP version 12.4.2) according to the manufacturer's procedures. Furthermore, the ALMI will be calculated as the sum of lean mass of arms and legs divided by height squared.

Physical performance On the same day, the SPPB test will be used to assess functional performance of the lower extremities. Each participant will performed: 4 m at usual customary gait speed, a five repeated chair-stands test and three standing balance tests (side by side, semi-tandem and tandem).

A digital dynamometer (CAMRY, Digital Hand Dynamometer model: EH101) will be used to assess HGS and all measurements were conducted by the same operator. Before starting, participants will observe a demonstration of the test procedure and engage in two practice attempts.

Knee muscle strength measurements and analysis An isokinetic dynamometer (CMSi Cybex Humac Norm Dynamometer, Lumex, Ronkokoma, NY, USA) will be used to assess the isokinetic strength of knee flexors and extensors muscles.

Maximal isokinetic knee extension-flexion tests will be performed in a randomised sequence at 60, 90, 150, 180 and 210°ˑs-1. Trials will consist in three knee extension-flexion movements with 60 s-recovery. The maximal strength of knee extensors muscle will be calculated with the Hill's hyperbolic function. The isokinetic knee extension-flexion power will be calculated as the product between strength and velocity. Finally, for knee extensors, maximal muscle power expressed in Watt, will be calculated from the power-velocity curve.

1-RM assessment Before starting training intervention, participants will perform three sessions of familiarization with the resistance isotonic machines. High intensity strength exercise (Exe-H) protocol: All the participants will performed a supervised progressive resistance training protocol, three times per week, 1 hour per session. Each participant will performed the same strength training protocol, starting with 3 sets of 8-10 repetitions at 70% of 1-RM (month 1), with a progressive increase of intensity at 75% of 1-RM (month 2 and month 3), and 80% 1-RM that will be maintained for the rest period of intervention. The compliance will be define as the number of exercise sessions expressed in % of the target value. Each participant will must reach a compliance above the 70% to be included in the final analysis.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participants will be included in the study based on the following inclusion criteria:

  • Older men and women between 60-80 years
  • The presence of sarcopenic obesity was considered when the following two conditions were satisfied: Fat mass > 34.8% and FFM <90% of subject's ideal FFM.
  • Resident in Verona (Italy)
  • Stable weight in the previous 2 months
  • Previously sedentary (less than one hour of exercise per week in the last 6 months)
  • Signing of the informed consent for participation in the study

Exclusion criteria

  • Unstable angina or recent myocardial infarction
  • Malignant or unstable arrhythmias
  • Heart failure NYHA class > II
  • Severe respiratory failure
  • Severe heart valve disease (i.e severe aortic stenosis or insufficiency)
  • Abdominal and/or thoracic aneurysm
  • Recent intracerebral or subdural haemorrhage
  • Poorly controlled arterial hypertension
  • Presence of pacemakers or metal prostheses
  • Severe chronic renal failure
  • Symptomatic musculoskeletal pathology
  • Symptomatic disc herniation, arthrosis, acute joint, tendon and ligamentous injuries, hip and/or knee prostheses recently placed (<6 months) or with joint instability, symptomatic or large inguinal or abdominal hernia
  • Acute retinal detachment or bleeding
  • Recent eye surgery (laser, cataract, retinal surgery, glaucoma surgery)
  • History of malignant cancer within the previous 5 years
  • Diagnosis of dementia
  • Eating disorders

Treatment and study plan

AA-1

Dietary Supplement

low dose aminoacids

AA-2

Dietary Supplement

high dose aminoacids

Placebo

Behavioral

Nutritional Placebo

Exe-H

Behavioral

high intensity physical exercise

Primary outcomes

  1. Change from baseline 1-repetition maximum with isokinetic dynamometer at 5-months

    Time frame: Month0, Month5

    Change in 1-repetition maximum test performed with isokinetic dynamometer in Kilograms

Secondary outcomes

  1. Change from baseline Short Physical Performance Battery at 5-months

    Time frame: Month0, Month 5

    Change in Short Physical Performance Battery Score

  2. Change from baseline in handgrip at 5-months

    Time frame: Month0, Month5

    Change in upper limb muscle strength measured with handgrip in kilograms

  3. Changesfrom baseline skeletal muscle mass at 5-months

    Time frame: Month0, Month5

    Change skeletal muscle mass measured with DXA in kilograms

  4. Change from baseline fat mass at 5-months

    Time frame: Month0, Month5

    Change fat mass measured with DXA in kilograms

  5. Change from baseline in mRNA at 5-months

    Time frame: Month0, Month5

    Change mRNA dosage

  6. Change from baseline in muscle power at 5-months

    Time frame: Month0, Month5

    Change in isokinetic muscle power of the lower limbs in kilograms

Sponsors and collaborators

Lead sponsor

Azienda Ospedaliera Universitaria Integrata Verona

Other

Collaborators

  • Azienda Ospedaliera di Padova
  • University of Milan
  • Università degli Studi di Brescia

Registry information

Acronym: MAYBE

Important dates

Study start
2019
Primary completion
2022
Study completion
2022
First posted
Jul 10, 2023
Registry last updated
Jul 10, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.